Article Text

PDF
Some dodgy claims for ▾ pirbuterol (exirel) - a β2 agonist

Abstract

Pirbuterol (Exirel - Pfizer) is a β2-adrenergic agonist marketed last year for the treatment of bronchial asthma, chronic bronchitis, and emphysema. Advertisements say ‘Exirel may go beyond the immediate relief of bronchospasm’, and that its beneficial effects on pulmonary circulation and the right heart ‘may ultimately help to break the destructive progression’ of these diseases to cor pulmonale and heart failure. The manufacturer also claims superiority over salbutamol because of its longer duration of action and its greater selectivity for lung tissue. The promotional tactics have been criticised in the Lancet.1

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.